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Summary
Objective: To ascertain the predictive role of longitudinally acquired biochemical measures of cartilage turnover in relation to X-ray deﬁned
knee osteoarthritis (OAK), knee pain and functioning.
Methods: This is a feasibility study based on 72 enrollees of the Michigan site of Study of Women’s Health Across the Nation (SWAN), a lon-
gitudinal, population-based cohort study with 11 annual visits to characterize health at the mid-life. At visits in 1996, 1998 and 2007, radio-
graphs were evaluated for the presence of OAK [2 on the Kellgren and Lawrence (KeL) scale]. Knee pain and stiffness were assessed
by interview. Functioning was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Cartilage olig-
omeric matrix protein (COMP) and Type II collagen telopeptides (CTX-II) were assayed in serum and urine samples collected on alternate
years from 1997 to 2006. We related trajectories of the cartilage biochemical markers from these ﬁve time points to OAK severity (no
OAK, KeL score< 2; mild OAK, KeL score¼ 2; moderate/severe OAK, KeL score¼ 3 or 4), pain, stiffness, or functioning, using longitudinal
non-linear mixed modeling.
Results: The 2007 prevalence of X-ray deﬁned OAK was 50% in these 72 women. Upward trajectories of COMP (P¼ 0.02) and CTX-II
(P¼ 0.006) were associated with increased OAK severity and body size. COMP trajectories were associated with pain and stiffness, but
not functioning. CTX-II trajectories were associated with stiffness scores, but not knee pain or functioning scores.
Conclusion: Multiple, biennial measures of COMP or CTX-II taken over a 10-year period were predictive of subsequent OAK and knee
stiffness.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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There has been substantial interest in the viability of mea-
suring degradation products of joint tissues, especially of
cartilage extracellular matrix. Two biochemical markers,
cartilage oligomeric matrix protein (COMP) and crosslinked
C-telopeptides of Type II collagen (CTX-II) are potentially
predictive of the development of knee osteoarthritis (OAK)
and its attendant pain. However, there are few studies
that have prospectively related biomarker measures of car-
tilage or collagen to X-ray deﬁned OAK, knee pain, stiffness
or functioning in relation to the development of OAK.
Functionally, COMP binds to type II collagen ﬁbers and
stabilizes the articular cartilage collagen ﬁber network.
Serum COMP has been reported to have increasingly
greater release into the synovial ﬂuid and serum in patients
with OA and rheumatoid arthritis1e7. Sharif et al. demon-
strated that serum COMP levels were signiﬁcantly higher
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1609those with non-progressive disease3 and that there was
an association between changes in COMP levels and radio-
graphic progression in OAK over 5 years8. COMP has been
shown to be positively correlated with 3-year changes in
joint space width9. Most recently, Hunter et al. demon-
strated that a single measure of increased COMP predicted
subsequent 30-month follow-up cartilage loss on magnetic
resonance imaging (MRI)10.
Urinary CTX-II, a biochemical marker of type II collagen
breakdown, has been negatively correlated with joint sur-
face area and was an important predictor of joint damage
assessed by radiographs11. Urinary CTX-II was signiﬁcantly
higher in participants with OAK compared to controls11.
More recent work has shown that increased CTX-II mea-
sures are related to OAK progression as assessed with
KeL scores12 or joint space width from radiographs13 and
cartilage loss from MRI14,15. Though some have suggested
that urinary CTX-II should be considered a bone marker
rather than a cartilage marker, the fourth and most critical
cartilage layer is at the bone interface and elevations of
CTX-II may represent the more compromised cartilage16.
Much of the current data with biomarkers is based on
a cross-sectional single-time assessment of biomarkers re-
lated to X-ray deﬁned OAK levels or with a single-time
baseline measurement of biomarkers related to subsequent
1610 M. F. Sowers et al.: COMP, CTX-II and osteoarthritis severityX-ray deﬁned OAK progression. There is a dearth of studies
with multiple longitudinal measurements of the biomarkers
related to the incidence or increased severity (assessed
with X-ray and/or clinical symptom report) of OAK in a pop-
ulation-based sample. For that reason, the aims of this fea-
sibility study were (1) to determine the likelihood that
longitudinal measures of COMP and CTX-II, measured in
specimens collected ﬁve times biennially over a 10-year pe-
riod predicted the incidence of X-ray deﬁned OAK, (2) to de-
termine if longitudinal measures of COMP and CTX-II were
related to OAK severity, and (3) to relate longitudinal mea-
sures of COMP and CTX-II to changes in knee pain, knee
stiffness, and knee functioning over a 10-year period.MethodsPOPULATIONMichigan SWAN is one of seven Study of Women’s Health Across the Na-
tion (SWAN) sites. SWAN is a multi-ethnic longitudinal study characterizing
the endocrinological, physiological and behavioral changes that occur during
the menopausal transition. Michigan SWAN includes a population-based
sample identiﬁed in two Detroit-area communities of southeast Michigan
who met the SWAN inclusion criteria. At baseline, women were aged
42e52, still menstruating, and not using exogenous hormone therapy. The
Michigan population-based cohort of 543 women has been followed with an-
nual assessments from baseline (1996e1997) through 10 follow-up visits.
Retention has been very good; the 10th follow-up visit included data collec-
tion from 83% of the still-living 525 participants. Michigan SWAN is the only
SWAN site that includes studies of OA.SAMPLEThis is a feasibility study using data from the ﬁrst 72 women with knee
X-rays from the Michigan SWAN cohort, examined between February 1
and June 1, 2007 who met the following three inclusion criteria: they had
at least ﬁve biennial serum and urine specimens collected at the time of their
annual SWAN visits between baseline and 2007 stored in a local repository;
knee X-rays in 1996/7 and 1998/9 as well as 2007; and arthritis-related inter-
view data for describing their knee pain, stiffness and functioning status at
the same three time points. This report represents 360 data points (ﬁve
per participant, biannually) over a 10-year period. Age, body mass index
(BMI), and ethnicity of these 72 women were not statistically different than
these characteristics in other women of the cohort. The University of Michi-
gan Institutional Review Board approved the study protocol and written in-
formed consent was obtained from each participant.MEASURESOA measures
OAK was deﬁned with the KeL scale17 in grading structural hard tissue
changes on X-ray images. Weight-bearing anterio-posterior radiographs ob-
tained in a semi-ﬂexed position18 were taken of both knees using General
Electric radiographic equipment in 1996/7 and 1998/9 (model X-GE MPX-
80; General Electric Medical Systems, Milwaukee, WI) and, in 2007, the AX-
IOMAristos radiographic systemwith integrated digital ﬂat detector technology
(Erlangen, Germany). Radiographs were evaluated independently by two
readers, with subsequent consensus reading for discordant scores. The in-
ter-rater reliability was in excess of 0.85. KneeX-rayswere scored for the pres-
ence of OA deﬁned by KeL scale depicted in the Atlas of Standard
Radiographs of Arthritis (0¼ normal, 1¼ doubtful OA, 2¼minimal OA,
3¼moderate OA, and 4¼ severe OA)17. This scale is based on the degree
of osteophyte formation, joint space narrowing, sclerosis, and joint deformity.
OAwasdeﬁnedas the presence of at least one kneewith a gradeof 2 or higher.
Women with knee replacement (n¼ 1) were classiﬁed as having severe OA.
Knee pain, stiffness and physical functioning
Knee pain was characterized by asking if women had knee pain and if it
occurred in more than 15 days of the month prior to interview19. Women were
categorized as having no knee pain (0), knee pain for less than 15 days per
month (1), or knee pain for more than 15 days per month (2). Stiffness was
based on responses to two questions that asked if women had morning knee
stiffness and whether that stiffness lasted more than 10 min. Women were
categorized as having no knee stiffness (0), knee stiffness for less than
10 min (1), or knee stiffness for 10 min or more (2). Knee functioning wascharacterized with the 17-item WOMAC index which had been scaled to
values between 0 and 10020,21. Women were apprised of their KeL X-ray
scores approximately 6 weeks following their interviews and imaging.
Assays
At each annual visit, blood and urine specimens were collected fasting,
between 7 a.m. and 11 a.m. and, whenever possible, in days 2e5 of the fol-
licular phase of the menstrual cycle. Cycles became too irregular to index
them against menstrual bleeding as women transitioned to the late meno-
pause transition stage, but the specimen collection protocol still included
the time of day and fasting requirements. Participants had been at rest for
at least 30 min prior to blood drawing. Blood specimens were centrifuged, ali-
quoted, and stored in ultralow freezers where they were maintained without
thawing until assay.
Urinary CTX-II was assayed with a competitive enzyme-linked immuno-
sorbent assay (ELISA) based on a monoclonal antibody raised against the
EKGPDP linear six-amino acid epitope of the type II collagen C telopeptide
(CartiLaps, Nordic Biosciences, Herlev, Denmark)22. Intra-assay coefﬁcients
of variation (CV) were 6%, 8% and 10% in the high, medium and low range of
measurements, respectively. Serum COMP was measured with a two-site
ELISA using native human COMP as the standard and immunogen
(COMPTM ELISA kit, AnaMar Medical)11. Intra-assay CVs were 2.6%,
3.3% and 7.1%, in the high, medium and low range of measurements, re-
spectively. uCTX-II values were adjusted for urinary creatinine measured
by a colorimetric assay. All samples from each individual were measured
in the same analytical run to avoid inter-assay variability.
Other measures
Weight and height, measured annually with a calibrated balance beam
scale and stadiometer, were used to calculate BMI [weight (kg)/height
(m)2]. Obesity was deﬁned as a BMI greater than 30 kg/m2.
Data analysis
Distributions of the measures of the biomarkers and body size were eval-
uated for presence of outliers and marked deviation from a normal distribu-
tion. Log transformations for the analytes and BMI were employed in data
analyses; following data analysis, the variables were back-transformed for
reporting the results unless otherwise noted.
Simple means and standard errors were used to describe the biomarkers,
age, body size, and functioning characteristics according to X-ray deﬁned
OAK scores. Frequencies of OAK and pain were tabulated. T tests were em-
ployed to assess the unadjusted differences in groups. Pearson correlations
and 95% conﬁdence intervals (CIs) were use to relate biomarkers to age and
BMI while Spearman correlations were used to relate the biomarkers to the
WOMAC physical functioning score.
A longitudinal mixed modeling approach was used to evaluate COMP and
CTX-II change over time in relation to theOA-related outcomes of interest. The
ﬁve biennial COMPandCTX-II values fromeachwoman, alongwith BMI, were
incorporated into proportional odds (after testing for and rejecting non-propor-
tional oddsmodel) ordinal logistic mixedmodels using ProcNLMixedwhen the
dependent variables were knee KeL score, pain score or stiffness score. For
these analyses, we had three time points (baseline and follow-up visits two and
10) for the knee KeL scores and ﬁve time points for the biochemical markers
(from follow-up visits two, four, six, eight and 10). Further, the logCOMP and
logCTX-II values were incorporated, along with BMI, into longitudinal mixed
models using Proc Mixed where the dependent variable was the continuous
measure of physical functioning fromWOMAC. The appropriateness of model
ﬁts were assessed both graphically and using residual analyses.
To estimate the predictiveness of the various levels of biomarkers’ change
over time in relation toX-ray deﬁnedOAK, eachwoman’s ﬁve valueswere ﬁtted
using mixed models (Proc Mixed) to generate a woman-speciﬁc intercept and
slope. Then, receiver operator characteristic (ROC) curves were employed to
display the sensitivity and1-speciﬁcity, or the truepositive rateagainst the false
positive rate, of these slope values for predicting incident OAK as identiﬁed in
the 2007X-rays (75%of the 72womenwho did not have aKeL score 2). The
c-statistic represents the probability, based on the area under the curve, that
those with greater markers change have OAK as compared to those without
OAK23. The c-statistic is a goodness-of-ﬁt measure of the ROC curve. Values
in excess of 0.60 indicate discrimination by the markers, but good discrimina-
tion is identiﬁed when values are in excess of 0.80.
SAS 9.1 and Macro facilities (SAS Institute, Cary, NC) were used to per-
form the statistical analyses and plot the ﬁndings.
Results
In 1997/8, the prevalence of X-ray deﬁned OAK
(KeL 2) was 25% with 20% having a KeL score¼ 2
(mild OA) and 5% had a KeL score> 2 (moderate to severe
Table I
Age, body size, and biochemical markers (characterized at 1997/1998 and 2007) and measures of knee pain, stiffness and functioning
(WOMAC) (2007), overall and by 2007 X-ray defined OAK status for 72 women from the Michigan site of the Study of Women’s Health Across
the Nation
Overall By OAK severity in 2007
No OAK (KeL¼ 0,1) Mild OAK (KeL¼ 2) Severe OAK (KeL¼ 3,4)
MeanSD MeanSD MeanSD MeanSD
At follow-up visit 02 (1997/8)
N 72 54 (75%) 14 (20%) 4 (5%)
Age (years) 47.5 2.6 47.4 2.6 48.1 1.9 47.2 3.4
BMI (kg/m2) 33.0 8.2 31.4 7.5 36.8 7.3 45.4 7.8
Obese (BMI 30) (n, %) 44 (61%) 29 (54%) 11 (78%) 4 (100%)
sCOMP (U/L) 8.8 3.0 8.7 3.11 9.1 2.7 9.4 2.9
uCTX-II/Cr (ng/mmol) 164.2 94.1 158.8 84.9 176.4 129.0 222.5 125.2
At follow-up visit 10 (2007)
N 72 36 16 20
BMI (kg/m2) 34.1 8.4 29.7 6.2 37.3 9.3 41.0 6.3
Obese (BMI 30) (n, %) 46 (66%) 15 (41%) 12 (75%) 19 (95%)
sCOMP (U/L) 9.7 3.5 9.0 2.8 10.0 4.2 10.8 4.3
uCTX-II/Cr (ng/mmol) 292.2 188.7 261.9 178.4 291.7 196.4 344.7 168.5
WOMAC physical functioning score 8.3 13.5 3.1 8.7 10.6 15.8 15.8 15.2
Knee pain (n, %)
Pain, 15 days per month 19 (26%) 3 (8%) 4 (25%) 12 (60%)
Pain, <15 days per month 10 (14%) 5 (14%) 2 (12%) 3 (15%)
No pain 43 (60%) 28 (78%) 10 (63%) 5 (25%)
Knee stiffness (n, %)
Stiffness, 10 min 26 (36%) 8 (22%) 6 (37%) 12 (60%)
Stiffness, <10 min 9 (12%) 2 (6%) 4 (26%) 3 (15%)
No stiffness 37 (52%) 26 (72%) 6 (37%) 5 (25%)
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OAK (KeL 2) was 50% with 22% of the sample having
a KeL score of 2 (mild OA) and 28% having a KeL
score> 2 (moderate to severe OA) (see Table I). In 2007,
the women with severe OA (KeL score 3 or 4) had
a mean WOMAC physical functioning score of 15.8 15.2
while the mean scores among those women with mild or
no OAK were 10.6 15.8 and 3.1 8.7, respectively. The
mean WOMAC score for the group with severe OAK was
statistically signiﬁcantly higher than the mean WOMAC
score for women without OA (P¼ 0.0003).Table I
Association of longitudinal measures of logCOMP and logCTX-II with radi
stiffness and pain score categories,
KeL OAK scores
b (95% CI) P-value b (95
Model #1: COMP
Intercept* 24.96 (34.61, 15.30) <0.0001 17.98 (25
Threshold2y 1.57 (1.04, 2.09) <0.0001 1.11 (0.8
logCOMP 1.69 (0.31, 3.08) 0.02 1.71 (0.4
logBMI 5.64 (3.32, 7.97) <0.0001 3.84 (1.7
Model #2: CTX-II
Intercept* 26.44 (36.86, 16.03) <0.0001 16.69 (24
Threshold2y 1.65 (1.10, 2.21) <0.0001 1.07 (0.7
logCTX-II 1.10 (0.33, 1.87) 0.006 0.56 (0.0
logBMI 5.44 (2.96, 7.91) <0.0001 3.70 (1.6
*The intercept for the X-ray deﬁned OAK KeL scores allowed a compa
for stiffness and pain allows a comparison of ordinal scores (0 vs 1e2).
yThe threshold2 variable compared KeL scores of 0e2 vs 3e4.; the thre
scores (0e1 vs 2).LONGITUDINAL TRAJECTORIESUsing longitudinal non-linear mixed modeling, the upward
trajectories of COMP and CTX-II, adjusted for BMI, were
statistically signiﬁcantly related to the severity of X-ray de-
ﬁned OAK, as shown in Table II. In the ﬁrst model, the inter-
cept allowed a comparison of the KeL scores of 0e1 vs
KeL scores of 2e4 and the threshold2 variable compared
KeL scores of 0e2 vs 3e4. This model incorporated
a test of the statistically signiﬁcant contribution of COMP
(P¼ 0.02) or BMI (P< 0.0001) to the odds of observing
these relationships. Similarly, the second modelI
ographic OAK KeL severity scores and clinical symptoms of knee
using non-linear mixed models
Knee stiffness Knee pain
% CI) P-value b (95% CI) P-value
.85, 10.11) <0.0001 18.45 (28.78, 8.12) 0.0007
1, 1.42) <0.0001 1.05 (0.65, 1.45) <0.0001
8, 2.93) 0.007 1.98 (0.29, 3.67) 0.02
1, 5.97) 0.0006 3.73 (1.06, 6.41) 0.007
.32, 9.06) <0.0001 17.14 (27.16, 7.13) 0.001
8, 1.37) <0.0001 1.03 (0.63, 1.43) <0.0001
2, 1.11) 0.04 0.56 (0.27, 1.40) 0.18
1, 5.79) 0.0007 3.77 (1.10, 6.45) 0.006
rison of the KeL scores of 0e1 vs KeL scores of 2e4; the intercept
shold2 variable for stiffness and pain allows a comparison of ordinal
Table III
Associations of logCOMP and logCTX-II with the WOMAC physical
functioning score (as a continuous measure)
WOMAC functioning score
b (95% CI) P-value
Model e COMP
Intercept 50.45 (81.21, 19.69) 0.0017
logCOMP 4.13 (0.64, 8.90) 0.09
logBMI 13.77 (5.25, 22.30) 0.0017
Model e CTX-II
Intercept 49.20 (79.87, 18.53) 0.002
logCTX-II 1.29 (0.92, 3.49) 0.25
logBMI 14.05 (5.60, 22.49) 0.001
Fig. 2. The ROC curve identifying the sensitivity and 1-speciﬁcity for
the measures of CTX-II slope in predicting X-ray deﬁned incident
OAK in 2007, with a c-statistic of 0.64 as an indicator of
goodness-of-ﬁt.
1612 M. F. Sowers et al.: COMP, CTX-II and osteoarthritis severityincorporated a test of the statistically signiﬁcant contribution
of CTX-II (P¼ 0.006) or BMI (P< 0.0001) to the odds of ob-
serving these relationships.
COMP and CTX-II trajectories, adjusted for BMI, were
statistically signiﬁcantly and positively associated with stiff-
ness scores, P< 0.007 and 0.04, respectively (Table II).
COMP trajectories were associated with increasing pain
(P< 0.02), but not functioning scores (Tables II and III).
CTX-II trajectories were not associated with knee pain or
physical functioning scores (Tables II and III).USING ROCs TO EXAMINE PREDICTIVENESSWe examined the sensitivity and speciﬁcity for change
over time in both COMP and CTX-II to predict the ‘‘gold
standard’’ X-ray deﬁned incident OAK (only those women
with KeL scores of 0e1 at baseline) and depicted the ﬁnd-
ings in ROC curves shown in Figs. 1 and 2. Change over
time in CTX-II was slightly better than change in COMP
over time in predicting X-ray deﬁned incident OAK, although
neither biomarker was highly predictive as shown with the
modest c-statistics of 0.60 for COMP and 0.64 for CTX-II.
Further, it was difﬁcult to identify a rate of change value
for either biomarker above which there was a greater likeli-
hood of observing incident OAK deﬁned by X-ray. Simulta-
neous inclusion of both biomarkers did not improve the
prediction as identiﬁed with a c-statistic of the same
magnitude.Fig. 1. The ROC curve identifying the sensitivity and 1-speciﬁcity for
the measures of COMP slope in predicting X-ray deﬁned incident
OAK in 2007, with a c-statistic of 0.60 as an indicator of
goodness-of-ﬁt.Discussion
Our ﬁve biennial measures of COMP and CTX-II from
specimens collected over a 10-year period demonstrated
progressive increases in proﬁles that were associated with
subsequent OAK disease severity, deﬁned from X-rays,
and joint stiffness. This suggests that both biomarkers pre-
dict the development of OAK in middle-aged women over
a 10-year period. We demonstrated that trajectories of
COMP and CTX-II over a 10-year period of time were sen-
sitive and speciﬁc for the prediction of incident X-ray de-
ﬁned OAK; however, the sensitivities and speciﬁcities
were modest and did not allow ready identiﬁcation of rates
of change that were likely to result in the identiﬁcation of in-
cident X-ray deﬁned OAK.COMPSerum concentrations of COMP have been considered
a potentially prognostic indicator of joint damage and used
to identify persons at higher risk of OA progression3,9,24,25.
Higher levels of COMP have been reported in cross-sec-
tional studies of persons with OAK26, in those with OAK
and post-traumatic knee injury compared to controls1 and
in differentiating persons with OAK but with synovitis vs no
synovitis27. While there have been numerous studies of col-
lagen markers, only three studies have related markers
measured over time to measures of radiographic OAK3,8,9.
Upward COMP trajectories have not been shown to be
highly speciﬁc for deﬁning the initiation of OAK nor to deﬁn-
ing the area of the joint where compromise is occurring.
One potential reason for this lack of speciﬁcity may be
that COMP expression can be identiﬁed in tissues other
than articular cartilage including ligaments, tendons, me-
nisci, and synovial membranes25,28 and pathology in these
tissues would be more effectively characterized using MRI
than radiographs. A recent study has shown a modest as-
sociation of COMP with MRI-deﬁned cartilage losses10.
This has lead investigators to speculate that COMP reﬂects
inﬂammation as well as soft tissue turnover14, a speculation
supported by the recent report that the metalloproteinase A
disintegrin and metalloproteinase thrombospondin
(ADAMTS-7) was found to bind directly to and degrade
1613Osteoarthritis and Cartilage Vol. 17, No. 12COMP29. However, COMP is not related to C-reactive pro-
tein an acute inﬂammatory protein of liver origin29.uCTX-IIMazieres et al.30 identiﬁed that patients with painful hip
OA in whom uCTX-II values were in the upper tertile of
the distribution had a greater risk of progression (odds ratio
(OR)¼ 3.7, 95% CI: 2.5, 5.6) than patients in the lower two
tertiles of the distribution. Further, a recent 5-year longitudi-
nal study reported average CTX-II values were greater in
progressors compared to non-progressors12. However,
Mazzuca et al.31 could not distinguish uCTX-II levels among
women who were characterized as progressors vs non-pro-
gressors in a study of obese women participating in a clinical
trial of OAK intervention. This contrast in ﬁndings may be re-
lated to assay characteristics as these studies did not use
the same assay.
Immunochemistry studies of CTX-II in animals and
humans indicate that the epitope is not only related to mol-
ecules at the cartilage surface but also the bone-to-cartilage
interface at the calciﬁed region32,33. As such, excretion of
uCTX-II may be greater among those with more severe
OAK that includes cartilage defects that have full penetra-
tion to the bone34. Single-time measures of uCTX-II have
been associated with severity of knee and hip OA13,30,35.
There are few longitudinal studies evaluating CTX-II
change in relation to knee deﬁned OA. Using four measures
at 6 months intervals in a 2-year trial of bisphosphonate,
there was a dose-dependent drop in uCTX-II observed at
the 6-month visit that was maintained for the ensuing 18
months36. Further, a 3-month change in CTX-II, along with
serum hyaluronic acid, predicted the 1-year change in
medial and lateral tibial cartilage thickness assessed with
MRI14.
Jung et al.37 identiﬁed that an uCTX-II value of 266 ng/
mmol creatinine had a speciﬁcity of 87.5% and sensitivity
of 75.5% for predicting X-ray deﬁned OAK, using the
same assay employed in our study. The mean value of
uCTX-II in our sample at baseline was lower than this
value; in contrast, the mean value was higher than this cut-
point value 10 years later when the prevalence of X-ray de-
ﬁned OA in our study was 50%. We provide new
information that indicates that while CTX-II change over
time is signiﬁcantly associated with X-ray deﬁned OAK,
its predictive capability for incident X-ray deﬁned OAK is
modest. Further, we could not identify an optimal cutpoint
above which the rate of uCTX-II had good sensitivity and
speciﬁcity.
This report has strengths and limitations. This was a study
to assess the feasibility of examining markers in relation to
the menopause transition hormone and thus includes only
women. The relatively small sample size precludes us
from testing interactions between the biomarkers and po-
tentially important variables representing change in weight
over the 10-year period. Strengths of the study include
the longitudinal nature of the study that includes measures
of characteristics important in OA including stiffness, joint
pain, and knee functioning measured concurrently with
the biomarkers. Other strengths include a subsample of
women who are in the age range where OAK is believed
to develop and followed sufﬁciently long to see that
development.
In summary, multiple, biennial measures of both sCOMP
and uCTX-II measured in specimens collected over a 10-
year period were associated with subsequent X-ray deﬁned
OAK and stiffness. Rarely are associations with stiffnessreported. sCOMP values, but not uCTX-II, were associated
with knee pain scores. Neither measure was associated
with the WOMAC-derived knee functioning score. However,
our evaluation of these biomarkers in relation to incident
X-ray deﬁned OAK suggests that their predictability is mod-
est. Thus, both sCOMP and uCTX-II change over time were
associated with the initiation and severity of OAK deﬁned by
X-ray, but had modest sensitivity and speciﬁcity in predict-
ing incident OAK.Conﬂict of interest
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